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The manipulation of the enteric microbiota with specific prebiotics and probiotics, has been shown to
reduce the host’s inflammatory response, alter brain chemistry, and modulate anxiety behaviour in both
rodents and humans. However, the neuro-immune and behavioural effects of prebiotics on sickness
behaviour have not been explored. Here, adult male CD1 mice were fed with a specific mix of non-
digestible galacto-oligosaccharides (Bimuno, BGOS) for 3 weeks, before receiving a single injection of
lipopolysaccharide (LPS), which induces sickness behaviour and anxiety. Locomotor and marble burying
activities were assessed 4 h after LPS injection, and after 24 h, anxiety in the light–dark box was assessed.
Cytokine expression, and key components of the serotonergic (5-Hydroxytryptamine, 5-HT) and gluta-
matergic system were evaluated in the frontal cortex to determine the impact of BGOS administration
at a molecular level. BGOS-fed mice were less anxious in the light–dark box compared to controls 24 h
after the LPS injection. Elevated cortical IL-1b concentrations in control mice 28 h after LPS were not
observed in BGOS-fed animals. This significant BGOS  LPS interaction was also observed for 5HT2A
receptors, but not for 5HT1A receptors, 5HT, 5HIAA, NMDA receptor subunits, or other cytokines. The
intake of BGOS did not influence LPS-mediated reductions in marble burying behaviour, and its effect
on locomotor activity was equivocal. Together, our data show that the prebiotic BGOS has an anxiolytic
effect, which may be related to the modulation of cortical IL-1b and 5-HT2A receptor expression. Our data
suggest a potential role for prebiotics in the treatment of neuropsychiatric disorders where anxiety and
neuroinflammation are prominent clinical features.
 2015 Published by Elsevier Inc.1. Introduction
A functional link between the intestinal microbiota and neu-
ronal function in central nervous system has been convincingly
established in recent years, which appears to stem notably from
alterations in the host immune response (Rhee et al., 2009;
Cryan and Dinan, 2012; Burnet and Cowen, 2013; Forsythe and
Kunze, 2013). Germ-free mice display a reduction in the ability
to clear pathogens (Fritz et al., 2011), an exaggerated hypothala
mic–pituitary–adrenal (HPA) reaction to stress (Sudo et al., 2004)
and altered anxiety behaviour (Bercik et al., 2010; Neufeld et al.,2011; Diaz-Heijtz et al., 2011). Furthermore, the brains of germ-
free animals contain microglia that appear less mature than those
of specific pathogen free (SPF) mice and the transcriptome of these
microglia also suggests that they are less mature (Erny et al., 2015).
By contrast, in a strain dependent manner the administration of
specific Bifidobacteria and/or Lactobacilli probiotic species, induce
anxiolytic and antidepressant-like actions in rodents and humans
(Messaoudi et al., 2011; Dinan et al., 2013; Savignac et al., 2014)
by seemingly altering key neurotrophic molecules or neurotrans-
mitter systems involved in anxiety behaviours (Bercik et al.,
2010; Bravo et al., 2011; O’Sullivan et al., 2011). Specific probiotic
strains also inhibit stress-induced elevations of plasma corticos-
terone (Gareau et al., 2007; Bravo et al., 2011; Messaoudi et al.,
2011) and a wider range of probiotics have been shown to have
anti-inflammatory actions (Konieczna et al., 2012).
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tion of specific intrinsic Bifidobacteria and Lactobacilli, may also dis-
play similar properties as specific products have been shown to
modulate the immune system and display anti-inflammatory
properties (Hardy et al., 2013; Kanauchi et al., 2013; Vulevic
et al., 2013). Importantly, we have recently demonstrated that
fructo-oligosaccharides (FOS) and a specific non-digestible
galacto-oligosaccharide formulation (Bimuno, BGOS), elevate the
levels of brain-derived neurotrophic factor (BDNF), as well as cen-
tral N-methyl-D-aspartate receptor (NMDAR) subunit expression
(Savignac et al., 2013). This study also demonstrated the prebiotic
properties of BGOS, by showing a significant growth of Bifidobacte-
ria after its administration. Furthermore, we have demonstrated
that BGOS intake reduces the cortisol awakening response, and
some emotional processes in healthy volunteers (Schmidt et al.,
2015). These findings, therefore, suggest that certain prebiotics,
and in particular, BGOS, may have anxiolytic effects, though this,
together with potential underlying mechanisms of action, have
not been explored.
Specific pro- and prebiotics have been shown to reduce the
levels of circulating pro-inflammatory cytokines such as
interleukin-1 (IL-1), IL-6 or tumour necrosis factor alpha
(TNF-a) (Hardy et al., 2013; Vulevic et al., 2013). Elevated levels
of these cytokines are associated with certain psychiatric
disorders (Rook et al., 2014; Stuart et al., 2015; Wohleb et al.,
2015). Thus, these findings suggest that the immuno-modulatory
action of certain pro- and prebiotics may be key to attenuating
inflammation-related aberrant behaviour. Notably, rodents
administered with a single, peripheral dose of lipopolysaccharides
(LPS) from Gram-negative bacteria, display ‘sickness behaviour’
where a reduction of locomotor activity within the first few hours
is a principal feature (Cunningham et al., 2009; Biesmans et al.,
2013). This effect is followed by longer term depressive-like
behaviour and anxiety. At 24 h post injection mice exhibit no overt
changes in locomotor behaviour, but do show increased
immobility in a forced swim test, as well as decreased sucrose pref-
erence and reduced marble burying activity, indicating a
depression-like state (Couch et al., 2015). This time point is
suitable for studying the impact of prebiotics as it minimises the
confounds associated with the acute reductions in locomotor
activity. Attenuation of this LPS-induced sickness behaviour is
associated with the normalization of exaggerated IL-1, IL-6 or
TNF production, which can be achieved through dietary
interventions (e.g. calorific restriction prior to LPS injections
(MacDonald et al., 2014)). Since exaggerated immune function
has been associated with several neuropsychiatric disorders
that are linked to altered glutamate and 5-HT neurotransmission
(Mitchell and Dinan, 2010; Marsden, 2011; Dantzer, 2012),
the ability to use prebiotics to modify neural function by
manipulating the gut microbiota, or via their possible direct effect
on the host gut mucosa, in a low cost and physiologically safe man-
ner, is an attractive proposition for the development of new
therapy.
Here we tested the potential of BGOS to prevent, or attenuate,
LPS-induced sickness and anxiety behaviour in mice. To provide
further insights into the mechanisms underlying prebiotic action,
we also measured the effect of BGOS on the concentration of key
cytokines in the frontal cortex and corticosterone in the plasma,
and evaluated the impact of the prebiotic on the cortical
glutamatergic and serotonergic systems. The frontal cortex was
chosen as a region of interest for its susceptibility to inflammatory
neuropathology (de Pablos et al., 2006), notably following
LPS administration, and for its role in many neuropsychiatric
disorders (Shelton et al., 2011; Couch et al., 2013a,b; Pan et al.,
2014).2. Material and methods
2.1. Animals
All experiments were carried out with local ethical approval
and a UK Home Office licence granted under the Animals (Scien-
tific Procedures) Act (1986). Male CD1 mice (25–30 g, 6–8-week
old, Harlan Orlac, UK), were housed 3 per cage (plexiglas cages
33  15  13 cm, L W  H) and maintained under standard con-
trolled laboratories conditions (12-h light–dark cycle, lights on at
7 a.m., 21 ± 1 C, humidity 50 ± 5%). The CD1 mouse is outbred
and displays a more exaggerated pro-inflammatory cytokine
response to LPS compared to other strains such as the C57Bl6
(Nikodemova and Watters, 2011). Male mice were used to
maintain consistency with our previous prebiotic studies in male
rats (Savignac et al., 2013), and with previous behavioural studies
using probiotics (Bravo et al., 2011; Savignac et al., 2014, 2015).
Social dominance, which may occur in group-housing and inter-
fere with sickness behaviour (Gibb et al., 2011; Wohleb et al.,
2012), was thoroughly monitored by trained experimenter
(Savignac et al., 2011) but no overt dominance behaviour was
observed in the home-cages throughout the experiment. Mice
were fed with standard mouse chow ad libitum and allowed
4–5 days habituation to the animal facility before receiving prebi-
otic treatment.2.2. BGOS administration
To minimize stress and reduce the likelihood of fatalities
associated with the gavage procedure (Damsch et al., 2011), a
pilot study was run to test that the administration of BGOS via
the drinking water sufficiently elevated faecal Bifidobacteria,
and to evaluate an appropriate control solution (see below).
The supplementation of drinking water with test compounds is
a non-invasive approach which has been previously used to
deliver other prebiotics (Bindels et al., 2012) and probiotics
(Rashid et al., 2014) to rodents. Since the BGOS mix used in
the current study consists of 48% w/w galacto-oligosaccharide,
26% lactose, 14% glucose and 12% galactose, a mixture of these
sugars in the same proportion in the absence of galacto-
oligosaccharides, was also tested. The enzyme used to
covert the lactose to galacto-oligosaccharides is removed by
means of filtration (Tzortzis et al., 2005), which circumvents
the need to correct for any contaminating protein within the
BGOS powder.
Pilot Study: Male mice, housed as described above, were pro-
vided with either drinking water containing BGOS, (1.3%, w/v,
Bimuno, Clasado, Reading, UK; n = 6), BGOS free sugars (BFS,
n = 6) or normal drinking water (n = 6), in addition to their normal
chow, for 3 weeks. The BGOS was freshly prepared daily by dissolv-
ing 13 g of BGOS powder in 1L of water. The BFS solution was also
freshly prepared by dissolving lactose (3.38 g), glucose (1.82 g) and
galactose (1.56 g) (each from Sigma–Aldrich, UK) in 1L of water.
Clean standard drinking bottles were then filled with an equal
quantity of the solution and provided to all cages. Fluid intake
was monitored daily by weighing drinking bottles to ensure all ani-
mals were drinking an equivalent quantity of fluid. The prebiotic
properties of BGOS have been extensively studied, and the product
has been consistently shown to selectively increase Bifidobacteria
and, to some extent, Lactobacilli in both humans and animals
(Tzortzis et al., 2005; Depeint et al., 2008; Vulevic et al., 2008,
2013; Silk et al., 2009; Savignac et al., 2013). The enumeration of
Bifidobacteria alone were therefore estimated in our pilot experi-
ment (see below).
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After the 3 week supplementation with test compounds, all
mice were culled and fresh faecal pellets were removed from the
large intestine. Total Bifidobacteria species were evaluated with
Beerens agar plates, a method that has recently been used to
enumerate these bacteria in human faecal samples from infants
supplemented with galacto-oligosaccharides (Stiverson et al.,
2014). Briefly, faecal pellets from each animal were weighed and
homogenised in PBS (1:10 w/v) and diluted in a 1:10 series in fresh
PBS. An aliquot of 0.1 ml of 3 dilutions each was plated on selective
Beerens agar plates in triplicate. They were then incubated at 37 C
for 48 h inside an anaerobic chamber containing anaerobic atmo-
sphere generation bags (Sigma Aldrich, UK). The colonies formed
were counted from the plates that had 30–100 colonies. The num-
ber of CFU/ml of culture for each treatment was calculated based
on the number of colonies and the corresponding dilution factor.
The values were then expressed as CFU/g faeces which was calcu-
lated from the original weight of the faecal matter sampled.
2.4. Experimental design and LPS injections
The schematic of the main study is presented in Fig. 1. Based on
the data from the pilot study (see Section 3.1), mice were provided
with normal drinking water or a BGOS solution with their standard
food. After 3 weeks of supplementation, all animals received drink-
ing water 24 h prior to LPS injections, to ‘wash-out’ any residual
circulating sugars, particularly glucose, absorbed from the BGOS
solution. This was a precautionary measure, although previous
studies have shown that the oral administration of 50 mg glucose
did not significantly alter blood sugars levels (Andrikopoulos
et al., 2008); in the current study, mice ingested an average of
13 mg glucose/day. The galacto-oligosaccharides in BGOS are not
absorbed by the intestines, but are readily metabolized by the
microbiota in the colon. BGOS has also been suggested to interact
directly with gut cells (Tzortzis, 2009). Therefore, the observed
effects of BGOS supplementation are likely to arise from either
the gut bacteria and/or direct interaction with the gut.
A single injection of 0.75 mg/kg LPS (E. coli 026:B6,
Sigma–Aldrich) in saline (0.9%), or saline alone, was administered
to mice by an intraperitoneal route, 4 h before behavioural testing
commenced. Four groups (n = 15 mice/group, 5 cages of 3 mice per
group) were tested: (1) water-fed/saline injected (Water/SAL); (2)
water-fed/LPS injected, (Water/LPS); (3) BGOS-fed/saline injected
(BGOS/SAL); and (4) BGOS-fed/LPS injected (BGOS-LPS). This
experiment was performed twice to provide a total of 30 mice
per test group for analysis.
Mice were tested for locomotor activity 4hrs post LPS/saline
injections, followed by the marble burying test 7hrs after the injec-
tion. This time-window was carefully chosen to enable behaviour
to be assessed at the peak of LPS-induced sickness and pro-
inflammatory cytokine release (Dantzer et al., 2008). Twenty-four
hours post injection, animals were tested in the light–dark boxFig. 1. Schematic of the experimental design. CD1 mice received standard chow ad libitum
Animals then received a single injection of either LPS (0.75 mg/kg) or saline 4 h prior to
test. The mice were then tested for anxious behaviour 24 h after the LPS or saline injectfor anxiety behaviour (Couch et al., 2015). The experimenter was
blind to treatment and remained in the experimental room silently
during testing. Animals were tested in a counter-balanced, pseudo-
random order with respect to cage and treatment groups. Animals
were culled 3 h post behaviour to assess the effects of LPS on brain
chemistry.
2.5. Locomotor activity (LMA)
The administration of LPS reduces LMA (Skelly et al., 2013), and
is often used as one measure of sickness behaviour. The test was
run in a transparent plexiglas box (48  27  21 cm, L W  H,
Photo Beam Activity Hardware and Software, Open Field San Diego
Instruments) covered with a transparent plexiglas top (perforated
for breathing) and containing a thin layer of sawdust bedding.
Room lighting was 60 ±5 lux. Four hours following LPS or saline
injections, each animal was gently placed individually into the
locomotor activity box and allowed to explore freely for 2 h. LMA
was recorded using photo-beams arranged across the box and is
expressed as the number of beam breaks made by the animals
per unit time (10 min bins). At the end of the test animals were
returned to their home cage to rest before the next behavioural
test. The LMA box was cleaned between animals with 70% ethanol
to remove odours.
2.6. Marble burying
Spontaneous digging by CD1 mice has been shown to be
impaired in IL-1b-mediated sickness behaviour (Cirulli et al.,
1998). A concomitant change in the cortical serotonin system has
also been shown with post-inflammatory impairment of digging
behaviour (Couch et al., 2015). We therefore applied the marble
burying paradigm to assess the effects of acute inflammation on
digging activity in mice, and the influence of BGOS supplementa-
tion thereon. The test was conducted 7hrs following LPS/saline
injection, as previously described (Njung’e and Handley, 1991;
Deacon, 2006). Twenty marbles were placed on top of 5-cm saw-
dust bedding in transparent plastic cages (44  28  12 cm,
L W  H), in 5 lines of 4, 2 cm away from each other and 2 cm
away from the edges of the cage. Testing occurred under normal
room lighting, (100 lux at 1 m above the floor), as previously
described (Deacon, 2006). Each animal was gently placed in the
cage with the marbles for 30 min, after which the number of mar-
bles buried to at least 2/3 of their surface was counted.
2.7. Light–dark box
This test was used to assess anxiety behaviour and is based on
the approach/avoidance conflict mice face between their attraction
for novelty and their fear for bright open arenas. This task has also
been shown to be sensitive to behaviours related to changes in the
serotonin system and cytokine concentrations in the frontal cortex
(Couch et al., 2013a). The apparatus consisted of a small blackwith either drinking water alone or water containing BGOS (1.3% w/v), for 3 weeks.
locomotor activity, which was followed after a period of rest by the marble burying
ion, in the light/dark box, and then sacrificed 3 h after.
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opening for access to the light part, 3  2.7 cm, W  H) and a
brighter open compartment (46.5  21  21 cm, L W  H). Test-
ing was performed under a slightly dim light (50 lux within the
bright compartment), as previously described (Strekalova et al.,
2004). Twenty-four hours following LPS or saline injections, each
animal was gently placed in the dark part of the light–dark box
and was free to explore the whole box for 5 min. The latency to
leave the dark area, number of transitions between the dark and
lights parts and the time spent in the light section were measured.
The criterion to enter any compartment was 4 paws in that com-
partment. Mice were returned to their home cage with cage mates
at the end of the procedure.
2.8. Tissue collection
Animals were sacrificed between 12 and 1 p.m., and 3hrs fol-
lowing light/dark box testing. Mice were gently removed from
their cages and swiftly culled by concussion and decapitation
within 30 s, in accordance with Home Office, UK, guidelines. An
experienced experimenter ensured that care was taken to avoid
unnecessary distress to the animals. Whole brains were immedi-
ately harvested and snap-frozen in cold isopentane on dry-ice
(Sigma–Aldrich, UK) before storage at 80 C until further analysis.
Trunk blood was collected in Ethylene Diamine Tetra Acetic Acid
(EDTA) tubes and spun for 15 min at 5000 rpm. Plasma was iso-
lated and stored at 80 C prior to analysis.
2.9. Cytokine assays
Each mouse cage (5 cages/group) yielded 3 brains of which one
from each cage was randomly selected for analysis. An additional
brain from each group was arbitrarily chosen to provide 6 brains
per group for investigation. This selection procedure was also car-
ried out with the replicate samples so that 12 brains (6 from each
replicate), from each of the 4 groups were processed. Frontal cortex
tissue from one hemisphere was removed with a scalpel on dry-ice,
weighed and homogenized in RIPA buffer (1:5 w/v, Sigma Aldrich,
UK) containing protease inhibitors (‘Complete-Mini’, Roche). Pro-
tein concentrations were determined using the Bradford reagent
(Sigma, UK). The concentrations of TNF-a, IL-1b, IL-6 and IL-10 in
all protein samples were measured using commercial ELISA kits
(R&D Systems), following pre-determined dilutions of the extracts
in respective assay buffer. All ELISAs were performed according to
manufacturer’s recommendations.
2.10. Western blotting
Western blots were performed on the cortical extracts used for
cytokine assays as previously described (Savignac et al., 2013).
Briefly, equal concentrations of protein extracts of cortex (5 lg)
from experimental and control groups (n = 12 samples/group)
were mixed with loading buffer (50 mM 1, 4-dithiothreitol and
0.025% bromophenol blue) and fractionated with a molecular
weight marker (GE Healthcare, Buckinghamshire, UK) by elec-
trophoresis on pre-cast 7.5% SDS/polyacrylamide gels (Biorad,
UK), and trans-blotted onto polyvinyl difluoride (PVDF) mem-
branes (Immobilon-P, Millipore, Watford, UK).
The membranes were blocked with 5% (w/v) non-fat milk in PBS
containing 0.1% Tween20 (PBST) for 45 min, and then incubated for
1 h at room temperature in incubation buffer (PBST with 2% [w/v]
milk) containing a primary antibody (diluted 1:1000) against one
of three NMDAR subunits: NR1 (AB9864, Millipore, UK, diluted
1:1000), NR2A (AB1555, Millipore, UK, diluted 1:2000) and NR2B
(AB15362, Millipore, UK, diluted 1:2000); the 5-HT1AR (ab85615,
Abcam, UK, diluted 1:2000), the 5-HT2AR (ab85496, Abcam, UK,diluted 1:1000) and b-actin (Sigma–Aldrich, UK, diluted
1:50,000). Membranes were then washed 3 times for 10 min in
PBST and incubated for 30 min in HRP-linked secondary antibody
in blocking buffer. Immunoreactive bands were visualized by
chemiluminescence using the ECL-Plus kit (GE Healthcare, Buck-
inghamshire, UK) and apposing membranes to X-ray film (Kodak
BioMax AR film). All antibodies produced a single band of expected
molecular weight. The optical densities (OD) of bands were mea-
sured using the AlphaImager 3400, and the data expressed as OD
ratios of NMDAR subunit: b-actin.
2.11. HPLC analysis
The levels of serotonin (5HT) and 5-hydroxyindole acetic acid
(5-HIAA) were measured in frontal cortex tissue dissected from
the brain hemisphere contralateral to that used for protein extrac-
tion (see above). Thus, a total of 12 samples per group (6 per repli-
cate, chosen as described for protein extraction), were subjected to
HPLC analysis as previously described (Nguyen et al., 2010), with
some modifications. Fragments of cortical tissue were homoge-
nized in 0.06 M perchloric acid (1:10 w/v) and then centrifuged
(14,000g, 5 min) to remove any tissue debris. All samples were
analysed using HPLC with electrochemical detection and separated
with an ACE column (C18, 3 lm, 125  3 mm + ACE C18 guard,
10  3 mm run at 35 C). The eluent was as previously described
(Nguyen et al., 2010) (9% methanol, 50 mM citric acid, 50 mM
H3PO4, 0.1 mM Na2EDTA, 2 mM 1-octanesulphonic acid, pH 3.2)
pumped with a flow rate of 0.6 ml/min (Shimadzu LC10 ADVP
HPLC Pump). Monoamines were detected using a porous graphitic
electrode held at +0.40 V (Coulochem 5100A). The sample content
was determined with reference to daily-calibrated standard solu-
tions in 0.06 M perchloric acid (5 pmol 5-HT and 5-HIAA). Chro-
matograms were displayed and analysed using Shimadzu LC
solution software.
2.12. Data analysis
All data are expressed as mean ± standard error of the mean,
and were analysed using SPSS software (version 19). Statistical
outliers (>3  SD) identified by the software were removed from
the analyses. Normal distribution of the data was assessed using
the Shapiro–Wilk test. Non-parametric data were subjected to
square-root transformation prior to analysis. The LMA data from
all four groups were analysed with an ANOVA which comprised
between subjects factors of ‘diet’ (water, BGOS) and ‘treatment’
(saline, LPS), and a within-subjects factor (repeated measure) of
‘time’. All other data were analysed in a standard 2-way ANOVA
with ‘diet’ and ‘treatment’ as between-subjects factors. Post hoc
Bonferroni comparisons were made where appropriate. In addi-
tion, analysis of simple main effects was also used to explore fur-
ther the basis of significant interactions from locomotor activity
data (Howell, 1997).3. Results
3.1. Pilot study on BGOS administration
The effect of supplementing drinking water with BGOS or BFS
compared to normal water on faecal Bifidobacteria numbers, is
shown in Fig. 2. One-way ANOVA followed by post hoc Bonferroni
comparisons revealed that there was a significant elevation of Bifi-
dobacteria in the BGOS-fed mice compared to BFS-fed (t = 4.57,
p < 0.05) and the water group (t = 5.06, p, 0.05) (Fig. 2A). There
were no statistical differences between the water and BFS-fed
groups (t = 0.49, p > 0.05). However, mice provided with a BFS
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Fig. 2. Effect of BGOS and control solutions on faecal Bifidobacteria numbers and
fluid intake in CD1 mice. (A) There was a significant effect of BGOS on faecal
Bifidobacteria numbers compared to mice provided with drinking water supple-
mented with BGOS free sugars (BFS), or water alone. (B) The fluid intake of mice
provided with a BFS solution for 3 weeks, was significantly greater that than those
provided with BGOS or water alone. Data are presented as mean ± SEM. ⁄p < 0.05,
⁄⁄p < 0.01. n = 6 mice/group.
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iod than BGOS (t = 3.59, p < 0.05) or water-fed animals (t = 3.86,
p < 0.05) (Fig. 2B). There was no statistical difference between
water and BGOS-fed mice (t = 0.27, p > 0.05). On the basis of these
findings, therefore, normal drinking water was used as a control in
the main experiment.3.2. Effects of LPS injection and BGOS intake on LMA and marble
burying behaviour in mice
The results of the 2 h LMA test are shown in Fig. 3A. LPS treat-
ment reduced locomotor activity compared to saline injected mice.
BGOS pre-treatment influenced the locomotor activity data but
these effects were complex and somewhat difficult to interpret.
An ANOVA with between subject factors of diet (water vs. BGOS)
and treatment (saline vs. LPS), and a within-subjects factor of
time (12 time bins of 10 min each), revealed a significant three-
way diet  treatment  time bin interaction (F11,1144 = 2.75;
p < 0.005), and a significant treatment  time bin interaction
(F11,1144 = 6.75; p < 0.0001), which reflected the fact that LPS treat-
ment reduced locomotor activity levels relative to saline treatment
between 20 and 40 min post-injection (analysis of simple main
effects; F1,104 > 3.97; p < 0.05 for time bins 20, 30 and 40 mins).
There was neither a significant diet  treatment interaction
(F1,104 = 0.003; p = 0.955), nor an overall effect of diet
(F1,104 = 0.01; p = 0.922), nor a main effect of treatment
(F1,104 = 1.09; p = 0.3).
To investigate further the basis for this significant 3 way inter-
action between diet, treatment and time, we ran separate two wayANOVAs to investigate specifically the effects of each diet and of
each treatment. A two-way ANOVA for the animals maintained
on a water diet (with LPS vs. saline treatment as a between sub-
jects factor, and time bin as a within-subjects factor) revealed a
significant interaction between LPS treatment and time bin
(F11,572 = 8.80; p < 0.0001) which was due to reduced locomotor
activity in the LPS treated mice at 30 and 40mins (simple main
effects; F1,52 > 5.94; p < 0.02). There was no overall main effect of
LPS treatment (F1,52 < 1; p > 0.50). In contrast, a two-way ANOVA
of LMA data from mice on the BGOS diet failed to reveal a signifi-
cant main effect of LPS treatment, or an LPS treatment by time bin
interaction (F11,572 < 1; p > 0.30). This would appear to suggest that
LPS treatment had no effect in BGOS fed mice. However, a separate
two way ANOVA comparing the effect of LPS treatment in water
and BGOS fed animals failed to reveal a significant difference
between these groups. There was no main effect of diet (BGOS
vs. water; F < 1; p > 0.93), and no interaction between diet and
time bin (F 11,572 = 1.13; p > 0.30) for LPS treated mice. Notably, a
two way ANOVA comparing BGOS and water diet for the saline
injected animals did reveal a significant diet by time bin interac-
tion (F11,572 = 2.57; p < 0.005), which was due to higher activity
levels in BGOS/SAL mice compared to Water/SAL mice at 70 and
80min post-injection (simple main effects; F1,52 > 4.82; p < 0.05).
Overall, these data did not convincingly demonstrate an influ-
ence of BGOS on the reduction of LMA following an LPS injection.
The decrease in LMA in water-fed mice following LPS was mild
and only significant 30 and 40 min after the endotoxin administra-
tion, relative to saline injected mice. Although this was not
observed in BGOS mice injected with LPS, the lack of a significant
difference between the BGOS/LPS and Water/LPS animals at these
and any other time points, precludes unequivocal conclusions to
be drawn.
In the marble burying test (Fig. 3B), there was no significant diet
 treatment interaction (F1,107 = 0.71, p = 0.40), though LPS treat-
ment alone did have a significant effect on marble burying
(F1,107 = 8.46, p = 0.004).3.3. Effects of LPS injection and BGOS intake on anxiety behaviour in
the light–dark box
The influence of LPS and BGOS on mouse behaviour in the light–
dark box is shown in Fig. 4.
Latency (Fig. 4A): There was a significant diet  treatment
interaction for latency to leave the dark compartment
(F1,107 = 9.44, p = 0.003), with significant effects of diet
(F1,107 = 10.62, p = 0.0015) and treatment (F1,107 = 8.70, p = 0.004)
alone. Post-hoc Bonferroni comparisons revealed that there were
significant differences between the Water/LPS vs BGOS/LPS ani-
mals, and the Water/SAL vs Water/LPS groups (p < 0.001), but not
BGOS/SAL vs BGOS/LPS or Water/SAL vs BGOS/SAL (p > 0.05).
Time in light (Fig. 4B): A similar pattern of results was obtained
for time spent in the light section. There was a significant diet 
treatment interaction for the time mice spent in the light compart-
ment (F1,107 = 4.34, p = 0.0396), with significant effects of diet
(F1,107 = 11.25, p = 0.0011) and treatment (F1,107 = 6.94, p = 0.01)
alone. Post-hoc Bonferroni comparisons revealed that there were
significant differences between the Water/LPS vs BGOS/LPS ani-
mals, and the Water/SAL vs Water/LPS groups (p < 0.01), but not
BGOS/SAL vs BGOS/LPS or Water/SAL vs BGOS/SAL (p > 0.05).
Transitions (Fig. 4C): There was no significant diet  treatment
interaction for the total number of crossings (transitions) between
the light and dark compartments (F1,107 = 0.83, p = 0.36). There was
neither a main effect of diet (F1,107 = 0.29, p = 0.59), nor a main
effect of treatment (F1,107 = 2.26, p = 0.14) for this total number of
transitions.
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The influence of LPS and BGOS on frontal cortex cytokine con-
centrations are shown in Fig. 5. For the levels of IL-1b (Fig. 5A)
there was a significant diet  treatment interaction (F1,42 = 4.946,
p = 0.035), with a significant effect of treatment (F1,42 = 9.365,
p = 0.005), but not diet (F1,42 = 2.821, p = 0.11). Post-hoc Bonferroni
comparisons revealed that there were significant differences
between the Water/LPS vs BGOS/LPS animals, and the Water/SAL
vs Water/LPS groups (p < 0.05), but not BGOS/SAL vs BGOS/LPS or
Water/SAL vs BGOS/SAL (p > 0.05).
There was no significant diet  treatment interaction for TNF a
levels, (F1,42 = 3.473, p = 0.073), though significant effects of diet
(F1,42 = 5.604, p = 0.025) and treatment (F1,42 = 4.428, p = 0.045)
alone were observed (Fig. 5B). There was neither a diet treatment
interaction (F1,42 = 2.33, p = 0.15), nor an effect of diet alone
(F1,42 = 1.03, p = 0.32) on the levels of brain IL-6 (Fig. 5C), thougha significant effect of LPS was observed (F1,42 = 5.878, p = 0.022).
Finally, there was neither a diet  treatment interaction
(F1,42 = 2.33, p = 0.15), nor an effect of diet (F1,42 = 1.03, p = 0.32)
nor treatment (F1,42 = 1.03, p = 0.32) on the levels of brain IL-10
(Fig. 5D).
3.5. Effects of LPS injection and BGOS intake on the levels of 5-HT
receptors and NMDAR subunits
The effects of LPS and BGOS feeding on cortical 5-HT1AR and 5-
HT2AR, and NMDAR subunits are shown in Figs. 6 and 7 respec-
tively. There was a significant diet  treatment interaction for 5-
HT2AR (F1,42 = 7.142, p = 0.013), with an effect of treatment
(F1,42 = 4.419, p = 0.046), but not diet (F1,42 = 1.409, p = 0.21). Post-
hoc Bonferroni comparisons revealed that there were significant
differences between the Water/LPS vs BGOS/LPS animals, and the
Water/SAL vs Water/LPS groups (p < 0.05), but not BGOS/SAL vs
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Fig. 4. BGOS supplementation attenuates LPS-induced anxiety in the light–dark
box. (A) Mice that had received normal drinking water, demonstrated an increased
latency to enter the lit area 24 h after an LPS injection, compared to BGOS
supplemented animals. There was a significant diet  treatment interaction. Bars
indicate significance between group differences after post hoc (Bonferroni) analysis.
(B) Mice that had received BGOS in their drinking water, spent more time in the lit
area compared to controls, 24 h after an LPS injection. There was a significant diet 
treatment interaction. Bars indicate significant group differences after post hoc
(Bonferroni) analysis. (C) LPS injection and BGOS supplementation did not affect the
number of transitions between the light and dark areas of the test apparatus. Data
are presented as mean ± SEM. All non-parametric data were square-root (sqrt)
transformed. ⁄p < 0.05. n = 28 mice/group for Water/SAL, Water/LPS and BGOS/SAL;
n = 27 mice/group for BGOS/LPS.
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nificant diet  treatment interaction for 5-HT1AR (F1,43 = 0.364,
p = 0.55), and no significant main effects of diet (F1,42 = 0.98,
p > 0.05) or treatment (F1,42 = 0.394, p > 0.05) .
The analysis of NMDAR subunits revealed that there were no
significant diet  treatment interactions for NR1 (F1,42 = 0.487,
p = 0.41), NR2A (F1,42 = 0.638, p = 0.39) or NR2B (F1,42 = 1.37,
p = 0.25). However, NR2B levels were affected by treatment
(F1,42 = 7.04, p = 0.014) and diet (F1,42 = 5.25, p = 0.031) alone.3.6. Effects of LPS injection and BGOS intake on cortical 5-HT and
5-HIAA levels
The cortical concentrations of 5-HT and 5-HIAA, and
5-HIAA/5-HT ratios are shown in Table 1. There were neither a diet treatment interaction nor main effects of diet or treatment on
cortical 5-HT (F1,42 = 0.002, p = 0.97; diet: F1,42 = 0.451, p > 0.05;
treatment: F1,42 = 2.666, p > 0.05), 5-HIAA (F1,42 = 0.211, p = 0.65;
diet: F1,42 = 2.031, p > 0.05; treatment: F1,42 = 0.032, p > 0.05) or
5-HIAA/5-HT ratios (F1,42 = 0.055, p = 0.82; diet: F1,42 = 0.037,
p > 0.05; treatment: F1,42 = 1.821, p > 0.05).4. Discussion
The current study examined the influence of the prebiotic BGOS
on LPS-induced sickness behaviour, anxiety and cytokine expres-
sion in mice. Our rationale was based on increasing evidence that
the gut microbiota plays an important role in the modulation of
immunity, and as such, in the regulation of behaviour. Here we
show that BGOS supplementation in mice attenuated post-
inflammation anxiety after a single injection of LPS, compared to
controls, as well as diminishing the LPS-mediated elevation of
IL1-b and 5-HT2ARs in the frontal cortex. Overall, these data
support the contemporary theory that the intestinal microbiota
are involved in the maintenance of normal brain function, and
confirms the notion that regulation of the immune system may
be integral to this action.
Post-inflammation anxiety in rodents is a well-known concept.
Bassi et al. (2012) have recently demonstrated that LPS injected
rats exhibit anxious behaviour in the light–dark box test, which
is consistent with our present study using mice. Our key finding,
that BGOS feeding prevented LPS-induced anxiety in the light–dark
box, is consonant with the action of anxiolytic and antidepressant
drugs in the same paradigm (Ohgi et al., 2013). Furthermore, our
data are in-keeping with a recent study showing that the oral
administration of specific probiotics prior to the induction of liver
inflammation, prevented deficits in social exploratory behaviour, a
feature of sickness behaviour (Wohleb et al., 2012). However, our
study is of particular significance because we show for the first
time the beneficial effects on behaviour following the proliferation
of indigenous gut bacteria, and that this was achieved with a natu-
ral, highly stable dietary compound.
The BGOS prebiotic mixture used in the current study contains
galacto-oligosaccharides that are resilient to temperature changes
and the harsh environment of the gastrointestinal tract. From our
data it is clear that the BGOS-mediated bacterial growth is suffi-
cient to impart robust immune and central effects. In contrast, pro-
biotics are more fastidious and very sensitive to environmental
changes, and so the number of viable microorganisms reaching
the large intestine following their ingestion can vary (Gueimonde
and Sánchez, 2012). Moreover, probiotics only promote the growth
of one or several beneficial bacteria, whereas BGOS augments the
proliferation of all (>30) Bifidobacteria species, and some Lacto-
bacilli, and is therefore likely to impart stronger influence on
neuro-immune interactions.
All microbes possess microbe-associated molecular patterns
(MAMPs, formally known as pathogen-associated molecular pat-
terns, PAMPs [Mackey and McFall, 2006]) which can be molecular
components of their cell wall (such as LPS on E. coli), bacterial flag-
ella, and/or microbial nucleic acids. The activation of pattern recog-
nition receptors by MAMPs initiates the innate immune response
which, in the case of the beneficial gut bacteria, may result in the
secretion of anti-inflammatory cytokines (Chu and Mazmanian,
2013) Although the mechanisms are uncertain, it is possible that
the Bifidobacteria, and indeed other commensals, express MAMPs
that do not fully activate the host enteric toll-like receptors (TLRs),
such as TLR4, that mediate a pro-inflammatory response, but have
sufficient affinity for the receptor to allow it to compete with
pathogenic MAMPs such as LPS. Clearly, the commensal microbiota
significantly contribute to the homeostasis of host immunity, but
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Fig. 5. Effect of BGOS supplementation on cytokine levels in the frontal cortex, 28 h after LPS or saline injections. (A) There was a significant diet  treatment interaction, and
cortical IL-1b levels in Water/LPS mice were significantly greater than in BGOS/LPS and Water/Sal animals. Bars indicate significant group differences after post hoc
(Bonferroni) analysis. (B) There was no diet  treatment interaction for TNF a levels, though a main effect of BGOS (not indicated) and LPS (indicated by bars) alone were
observed. (C) There were neither a diet  treatment interaction nor a main effect of BGOS for IL-6 concentrations, but an effect of LPS was observed (indicated by bars). (D)
There were neither a diet  treatment interaction nor main effects of BGOS or LPS on IL-10 concentrations. Data are presented as mean ± SEM. ⁄p < 0.05. n = 12 mice/group for
Water/SAL and BGOS/SAL; n = 11 mice/group for Water/LPS and BGOS/LPS.
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brain are still unclear.
Microglia are the resident macrophages of the CNS and their
activation results in the increase of pro- and anti-inflammatory
cytokines. A systemic injection of LPS, leads to the elevation of cir-
culating pro-inflammatory cytokines, such as Il-1b and TNF a,
which trigger the local production of cytokines in the CNS by stim-
ulating the microglia (Prinz et al., 1999). Thus, if the peripheral
innate immune response is abrogated by the increased activity of
commensal microbiota, as is likely to be the case here, then circu-
lating levels of IL-1b and TNF a, and macrophage activity would
remain unaltered following LPS, and microglia would not be acti-
vated. We have therefore provided compelling evidence for the sig-
nificant role of microbiota in the modulation of neuro-immune
interactions. Recent investigations using germ-free mice
demonstrated that in the absence of gut bacteria, the development
and maturation of microglia are impaired, and their response to
endotoxin is exacerbated (Erny et al., 2015). The study further
demonstrated that a systemic injection of short-chain fatty acids
(SCFAs), the products of bacteria-fermented dietary fibres, to
germ-free mice, rectified aberrant microglia morphology and func-
tion. Given that high concentrations of SCFAs are generated
from the microbial metabolism of prebiotics (McCarty and
DiNicolantonio, 2015), it is possible that these metabolites
contributed to the effects seen in our study.
However, since the expression of SCFA receptors are low or
absent in the brain (Erny et al., 2015), it is likely that these mole-
cules have indirect effects on the CNS. For instance, SCFAs release
the gut hormone, glucagon-like peptide-1 (GLP-1) (McCarty and
DiNicolantonio, 2015), which has both neurotrophic (Savignacet al., 2013) and anti-inflammatory (Dai et al., 2014) actions. Thus,
GLP-1 may be a key mediator linking the microbiome to the brain.
Another proposed mediator of microbiome-gut-brain axis commu-
nication is the vagus nerve, which physically connects the gut and
the brain stem. Vagotomy in mice has been reported to mitigate
the psychotropic effects of certain probiotics (Bravo et al., 2011).
In this instance, the microbiota may stimulate the vagal nerve end-
ings in the intestine via the aforementioned products of microbial
metabolism, or even through neurotransmitters produced by the
microbes themselves (Cryan and Dinan, 2012). Vagal nerve activa-
tion has also been shown to attenuate the effects of central pro-
inflammatory cytokines (Garcia-Oscos et al., 2015). Clearly, further
research is required to ascertain the mediator(s) of the BGOS
effects seen in the current investigation.
We have previously demonstrated an increase of 5-HT2AR
expression in the rat cortex, 6 h after an LPS injection (Couch
et al., 2013b) and in the mouse 24 h after LPS (Couch et al.,
2015). Here we have confirmed that cortical 5-HT2ARs increase
with acute inflammation, and have demonstrated that the effect
is sustained for 28hrs post-injection. Based on previous findings,
we suggest that this elevation of cortical 5-HT2ARs is involved in
the central pathophysiological effects of inflammation. Pharmaco-
logical evidence supports the role of 5-HT2 receptors in the modu-
lation of anxiety and depression, and non-selective antagonists
such as ritanserin and ketanserin are anxiolytic in rodents
(Griebel et al., 1997; Nic Dhonnchadha et al., 2003). Furthermore,
5-HT2AR knockout mice are less anxious than controls in the
light–dark box test, and the re-introduction of this receptor into
the cortex of these mice restores normal anxious behaviour
(Weisstaub et al., 2006). These data suggest, therefore, that the
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Fig. 6. Effects of BGOS supplementation on the 5-HT2AR and 5-HT1AR in the frontal
cortex, 28 h after LPS or saline injections. (A) Representative western blot images of
5-HT2ARs in each group (top panel), and receptor:b-actin ratios, following
densitometry of western blot images (bottom panel). There was a significant diet
 treatment interaction, and cortical 5-HT2AR levels in Water/LPS mice were
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treatment interaction nor main effects of BGOS or LPS on 5-HT1AR concentrations.
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Fig. 7. Effects of BGOS supplementation on NMDAR subunits in the frontal cortex
28 h after LPS or saline injections. (A) Representative western blot images of NR1
subunits in each group (top panel), and NR1:b-actin ratios, following densitometry
of western blot images (bottom panel). There were neither a diet  treatment
interaction nor main effects of BGOS or LPS on NR1 levels. (B) Western blot images
and NR2A:b-actin ratios in the frontal cortex. There were neither a diet  treatment
interaction nor main effects of BGOS or LPS on NR2A concentrations. (C) Western
blot images and NR2B:b-actin ratios in the frontal cortex. Main effects of BGOS (not
indicated) and LPS (indicated by bars) alone were observed. Data are presented as
mean ± SEM. ⁄p < 0.05. n = 12 mice/group for Water/SAL (WS in top panel) and
BGOS/SAL (BS); n = 11 mice/group for Water/LPS (WL) and BGOS/LPS (BL).
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rent study, may underlie the post-inflammatory anxiety displayed
in the light–dark box. Mechanistically, LPS-mediated anxious
behaviour in rodents has been associated with hyper-excitability
of the frontal cortex (Garcia-Oscos et al., 2015). Since the pharma-
cological stimulation of 5-HT2ARs expressed on pyramidal cells in
the prefrontal cortex can increase the local release of glutamate
(Mocci et al., 2014), it is reasonable to suggest that the elevation
of these receptors contribute to inflammatory cortical hyper-
excitability.
Although the mechanisms underlying the modulation of 5-
HT2ARs by acute inflammation remain elusive, our data suggest
a putative role of IL-1b, since the suppression of this cytokine by
BGOS coincides with the normalisation of 5-HT2ARs levels. The
mechanism by which BGOS alters cytokine expression in the brain
following LPS is likely to be mediated by its impact on peripheral
cytokine expression, through the mechanisms discussed above.
BGOS has been shown to reduce TNF-induced IL-8 and MIP-3a
Table 1
Cortical 5-HT and 5-HIAA concentrations following the oral administration of water
or BGOS and a single injection of saline or LPS. Data are expressed as means ± SEM.
The number of mice/group are indicated in parentheses.
[nmol/g Tissue]
Water/SAL Water/LPS BGOS/SAL BGOS/LPS
(n = 12) (n = 11) (n = 12) (n = 11)
5-HT: 2.17 ± 0.39 0.99 ± 0.11 1.95 ± 0.46 1.49 ± 0.33
5-HIAA: 0.76 ± 0.16 0.39 ± 0.04 0.95 ± 0.13 1.08 ± 0.30
5-HIAA/5-HT: 0.35 ± 0.05 0.31 ± 0.06 0.38 ± 0.08 0.52 ± 0.10
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(Tzortzis, 2009). The intraperitoneal administration of IL-1b has
been shown the induce sickness behaviour in rodents in a manner
that is dependent on the synthesis of IL-1b within the CNS (Bluthé
et al., 1995), and thus any BGOS-induced reduction in peripheral
IL-1b expression, by dampening the host-immune response, would
be likely to alter IL-1b expression within the brain.
The interaction between IL-1b and 5-HT2AR has been implied
by studies demonstrating that the intracerebroventricular infusion
of IL-1b into rats, induces a hyperthermic response that can be
blocked by 5-HT2AR antagonists (Chio et al., 2005). However, the
molecular basis for this association remains elusive. The current
study investigated NMDARs as potential intermediaries of the
observed LPS and BGOS effects, since they interact with
5-HT2ARs (Yuen et al., 2008), mediate neurotoxicity in central
inflammation (Ma et al., 2014), and are modulated by BGOS
(Savignac et al., 2013). In our study, the main effect of LPS was to
increase cortical NR2B subunits, which is consistent with earlier
observations (Harré et al., 2008; Tanaka et al., 2011), and may have
resulted directly from the observed elevation of brain
IL-1b (Viviani et al., 2006). If this change enhanced NMDAR func-
tion, then it could be reasoned that the elevation of 5-HT2ARs
was a homeostatic response to counterbalance NMDAR mediated
excitotoxicity. The reduction of IL-1b by BGOS seen in the current
study, and by others (Vulevic et al., 2013), may have then
attenuated the NMDAR response, and subsequent 5-HT2AR
changes. Although further investigations to elucidate the
central mechanisms underlying the anxiolytic effect of BGOS
post-inflammation are required, there is no doubt that the anti-
inflammatory action of this prebiotic is an important factor.
While effects on conditional, ethological test of anxiety (light/-
dark box) were clearer, our data on the effect of BGOS on LMA dur-
ing LPS-mediated sickness, were equivocal. The significant three-
way interaction between BGOS feeding, LPS injection and time,
suggested that the prebiotic influenced the action of LPS on LMA.
The reduced LMA in Water/LPS compared to Water/Sal was not
apparent in corresponding BGOS-fed animals, and on face, might
be interpreted as an attenuation of the LPS effect by BGOS.
However, although prior exposure to a BGOS diet influenced
subsequent LMA data, it was not simply the case that BGOS pro-
tected against LPS-induced hypoactivity. It was also clear from
the current study that BGOS supplementation did not affect
LPS-mediated reductions in marble burying behaviour. One inter-
pretation is that the prebiotic only influences anxiety-related
behaviours which involve an approach/avoidance conflict, and
not other behaviours potentially related to emotionality, such as
marble burying, but this would require further investigation.
Overall, the anxiolytic and anti-inflammatory effects of BGOS in
the current study were in-keeping with the actions of certain pro-
biotics that reduce inflammation or anxiety (Bercik et al., 2010;
Cryan and Dinan, 2012; Wang and Kasper, 2014). However, BGOS
only had a discreet behavioural effect in the animals that did not
receive LPS (cf. LMA of BGOS/SAL vs Water/SAL at 70 and
80 min). This was surprising in view of our recent data showingthat BGOS administration to healthy human volunteers, improved
emotional processing (Schmidt et al., 2015), and that Bifidobacteria
probiotics have anxiolytic effects in healthy animals (for review see
Cryan and Dinan, 2012). The latter discrepancy may arise from the
different mouse strains used in each study. The mice in the probi-
otic study are known to be innately anxious and display greater
anxiety than other mouse strains (Jacobson and Cryan, 2005;
Savignac et al., 2011, 2014; Ohland et al., 2013). Thus, a pre-
existing high basal level of anxiety may be required to reveal the
anxiolytic action of pre- and probiotics.5. Conclusions
We have demonstrated that dietary supplementation with the
prebiotic BGOS, attenuated anxiety, but not marble burying beha-
viour, in mice receiving a single injection of LPS. The beneficial
effects of BGOS on behaviour were most prominent in the late-
stage response to LPS, which has been likened to post-infection
fatigue (Couch et al., 2015). The prebiotic also prevented the LPS-
mediated increase in IL-1b and 5-HT2AR expression in the frontal
cortex, in the absence of altered 5-HT metabolism. Our study has
revealed a more direct link between the IL-1b and altered 5-
HT2AR receptor expression than previously envisaged. Moreover,
in spite of its molecular links with both IL-1b and 5-HT2AR, the
NMDAR did not appear to be involved in the combined effects of
LPS and BGOS in the current study. We therefore propose that
the anxiolytic action of BGOS on LPS injected mice was the result
of the prebiotic’s anti-inflammatory properties, which suppressed
the increase of IL-1b, and subsequent elevation of 5-HT2ARs that
may underlie post-inflammatory anxiety behaviour. Our results
therefore provide further compelling evidence for the central
benefits of BGOS supplementation.Acknowledgments
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